Pear Therapeutics (PEARQ) 10-Q 2022 Q2 Quarterly report

Certification of Periodic Financial Report

Pursuant to 18 U.S.C. Section 1350

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Each of the undersigned officers of Pear Therapeutics, Inc. (the “Company”) certifies, to his knowledge and solely for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2022 complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 11, 2022

/s/ Corey M. McCann

Dr. Corey M. McCann

Chief Executive Officer

(Principal Executive Officer)

Dated: August 11, 2022

/s/ Christopher D.T. Guiffre

Christopher D.T. Guiffre

Chief Financial Officer

(Principal Financial Officer)